<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02462525</url>
  </required_header>
  <id_info>
    <org_study_id>M14-467</org_study_id>
    <secondary_id>2014-002609-39</secondary_id>
    <nct_id>NCT02462525</nct_id>
  </id_info>
  <brief_title>Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma</brief_title>
  <official_title>A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1/1b, open-label, dose-escalation study designed to evaluate the safety,
      pharmacokinetics, and to determine the recommended Phase 2 dose of ABBV-838 in subjects with
      relapsed and refractory multiple myeloma.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    No Go decision for ABBV-838
  </why_stopped>
  <start_date type="Actual">May 6, 2015</start_date>
  <completion_date type="Actual">December 6, 2016</completion_date>
  <primary_completion_date type="Actual">December 6, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax) of ABBV-838</measure>
    <time_frame>Cycle 1 Day 1 (C1D1) and C3D1 pre- and post-dose; C1D4, C1D8, C1D15, C2D1, C2D15, C3D4, C3D8, C3D15, C4D1, and all subsequent ABBV-838 pre-dose dosing cycles</time_frame>
    <description>The maximum plasma concentration (Cmax: measured in ng/ml) is the highest concentration that a drug achieves in the blood after the first dose, but before administration of a second dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose of ABBV-838</measure>
    <time_frame>Up to 2 years from first dose of study</time_frame>
    <description>The highest dose level at which less than 2 of 6 subjects or less than 33% of (if cohort is expanded beyond 6) subjects experience a dose limiting toxicity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Preliminary activity of ABBV-838 monotherapy</measure>
    <time_frame>At screening, Cycle 1 Day 15 (C1D15), C3D15, C4D1, and for subjects who have been on ABBV-838 for ≥ 6 cycles, radiologic tumor assessments may be performed every 3 cycles per Investigator discretion up to approximately 3 years</time_frame>
    <description>Response evaluation will be based on International Myeloma Working Group (IMWG) Response Criteria.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>ABBV-838 dose escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Varying doses of ABBV-838</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABBV-838 plus pomalidomide/dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABBV-838 to be evaluated with pomalidomide/dexamethasone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABBV-838</intervention_name>
    <description>Varying doses of ABBV-838</description>
    <arm_group_label>ABBV-838 dose escalation</arm_group_label>
    <arm_group_label>ABBV-838 plus pomalidomide/dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pomalidomide</intervention_name>
    <description>Administered orally per the label.</description>
    <arm_group_label>ABBV-838 plus pomalidomide/dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Administered orally per the label.</description>
    <arm_group_label>ABBV-838 plus pomalidomide/dexamethasone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eastern Cooperative Oncology Group Performance Status of 0 to 2

          -  Not eligible for stem cell/bone marrow transplant or have refused stem cell/bone
             marrow transplant or have relapsed after autologous or allogeneic stem cell/bone
             marrow transplant

          -  Eligible for and agree to BM aspirate prior to treatment start

          -  Measurable disease M component in serum (≥ 0.5 g/dL) and/or urine (≥ 0.2 g excreted in
             a 24 hour collection sample)

          -  Must have received at least 3 prior lines of therapy including a proteasome inhibitor
             and an immunomodulatory agent or those who are double refractory to a PI and an
             immunomodulatory agent and have demonstrated disease progression (DP) on or within 60
             days of completion of the last therapy; participants previously treated with an
             alkylating agent, in addition to an IMiD or proteasome inhibitor, are allowed to
             enroll in the trial

          -  Participants must have adequate liver, kidney, and bone morrow function

          -  Participants with a history of chronic heart failure must have cardiac ECHO indicating
             left ventricular ejection fraction (LVEF) ≥ 45% within 21 days prior to first dose of
             study drug

          -  Participants in the combination therapy arms must be eligible to receive
             pomalidomide/dexamethasone, bortezomib/dexamethasone or lenalidomide/dexamethasone or
             other approved agents per current prescribing information for MM.

          -  Participants who will receive combination therapy with Pomalidomide/Dexamethasone must
             have received at least two prior therapies including lenalidomide and a proteasome
             inhibitor and have demonstrated disease progression on or within 60 days of completion
             of the last therapy

        Exclusion Criteria:

          -  Received anti-cancer therapy including chemotherapy, immunotherapy, radiation,
             biologic, any investigational therapy or herbal therapy within a period of 21 days
             prior to the first dose of ABBV-838, and have unresolved toxicities ≥ grade 2

          -  Concurrent metastatic solid tumors

          -  Non-Measurable M Protein (serum or urine) and measurable sFLC (&lt; 100 mg/mL)

          -  Major surgery within 21 days prior to the first dose of ABBV-838

          -  Clinically significant uncontrolled condition(s) including but not limited to the
             following:

        Grade ≥ 3 peripheral neuropathy or grade 2 peripheral neuropathy with pain Uncontrolled
        hypercalcemia Active uncontrolled infection Symptomatic congestive heart failure Unstable
        angina pectoris or cardiac arrhythmia Psychiatric illness/social situation that would limit
        compliance with the study

          -  Major immunologic reaction to any IgG containing agent or auristatin based agent

          -  Participants who are taking strong CYP3A4 inhibitors

          -  Positive for HIV (Human Immunodeficiency Virus) or with active hepatitis B and/or C

          -  Corneal pathology that would limit evaluation of loss in visual acuity associated with
             corneal deposits.

          -  Prior exposure to pomalidomide for subjects enrolling in the
             pomalidomide/dexamethasone combination arm.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Chicago Medical Center /ID# 139403</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Medical Center /ID# 139402</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine /ID# 135708</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110-1093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center /ID# 133569</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Sarah Cannon Research Institute /ID# 135814</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille, Hopital Claude Huriez /ID# 133634</name>
      <address>
        <city>Lille Cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes, Hotel Dieu - HME /ID# 133633</name>
      <address>
        <city>Nantes Cedex 1</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de la miletrie, Centre d'investigation clinique /ID# 147542</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Koeln /ID# 141535</name>
      <address>
        <city>Cologne</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetklinikum Dresden /ID# 141860</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Heidelberg /ID# 140046</name>
      <address>
        <city>Heidelberg</city>
        <zip>69210</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Schleswig-Holstein /ID# 141534</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Tuebingen /ID# 141074</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Wuerzburg /ID# 141533</name>
      <address>
        <city>Wuerzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona /ID# 141643</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de la Princesa /ID# 140881</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre /ID# 140878</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Universitaria de Navarra /ID# 141411</name>
      <address>
        <city>Pamplona-Navarra</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario Salamanca /ID# 140880</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 26, 2015</study_first_submitted>
  <study_first_submitted_qc>June 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2015</study_first_posted>
  <last_update_submitted>January 11, 2018</last_update_submitted>
  <last_update_submitted_qc>January 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>relapsed multiple myeloma</keyword>
  <keyword>antibody drug conjugate</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Pomalidomide</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

